| 28 GAAP to Non-GAAP Financials for the Six Months Ended June 30 AMAG Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations (unaudited, amounts in thousands, except per share data) Six Months Ended Six Months Ended June 30, 2015 June 30, 2014 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Revenues: Makena $ 119,103 $ - $ 119,103 $ - $ - $ - Feraheme and MuGard 42,964 - 42,964 40,007 - 40,007 License fee, collaboration and other revenues 51,322 (39,965) 8 11,357 5,630 (3,948) 8 1,682 Total revenues 213,389 (39,965) 173,424 45,637 (3,948) 41,689 Costs and expenses: Cost of product sales 40,705 (34,261) 9 6,444 5,580 (1,093) 9 4,487 Research and development 15,172 (1,691) 10 13,481 11,038 (842) 10 10,196 Selling, general and administrative 63,913 (9,866) 11 54,047 33,775 (4,696) 11 29,079 Acquisition-related 2,653 (2,653) 12 - - - - Restructuring 1,014 (1,014) 13 - - - - Total costs and expenses 123,457 (49,485) 14 73,972 50,393 (6,631) 43,762 Operating income (loss) / Adjusted EBITDA 89,932 9,520 99,452 (4,756) 2,683 (2,073) Other income (expense): Interest expense (20,572) 5,832 15 (14,740) (4,527) 2,652 15 (1,875) Other income, net 445 (2) 443 634 (116) 518 Total other income (expense) (20,127) 5,830 (14,297) (3,893) 2,536 (1,357) Net income (loss) before income taxes 69,805 15,350 85,155 (8,649) 5,219 (3,430) Income tax expense (benefit) 23,643 (23,025) 16 618 - - - Net income (loss) / Cash earnings $ 46,162 $ 38,375 $ 84,537 $ (8,649) $ 5,219 $ (3,430) Net income (loss) / Cash earnings per share: Basic $ 1.60 $ 2.92 $ (0.40) $ (0.16) Diluted $ 1.23 $ 2.27 $ (0.40) $ (0.16) Weighted average shares outstanding Basic 28,934 28,934 21,875 21,875 Diluted 40,791 37,182 21,875 21,875 |